Starpharma secures expanded deal with AstraZeneca
Starpharma (ASX:SPL) has revealed that AstraZeneca is evaluating using its dendrimer nanotechnology platform for a second oncology drug.
AstraZeneca is evaluating incorporating Starpharma’s DEP dendrimer drug delivery technology into one of the cancer treatments in its portfolio.
Commercial terms of the agreement have not been disclosed.
The two companies signed an agreement in September 2012 giving AstraZeneca the right to evaluate using the platform for one of the cancer drugs in its development pipeline. This new agreement will extend the research to a second drug.
“AstraZeneca are a global leader in oncology treatment and we are very pleased to be expanding our relationship with them focused on improving the delivery and performance of oncology treatments,” Starpharma CEO Dr Jackie Fairley said.
Reformulating chemotherapies with Starpharma dendrimers has the potential to reduce side effects while improving efficacy, tumour targeting and water solubility.
Starpharma is using the platform to develop a dendrimer-infused version of popular chemotherapeutic docetaxel (Taxotere). The company secured approval in January to conduct the first human trials of the formulation.
Breast augmentation procedure uses 3D-printed scaffolds
3D-printed scaffold technology from medtech company BellaSeno has been used in a primary breast...
Victoria detects H5N1 avian influenza strain
It follows disease confirmation in seabirds in WA, SA, NSW and Qld and the national decision that...
TGA acts on melatonin imports with infringement notices totalling $99K
Laboratory testing of several imported unregistered melatonin products has confirmed them to be...
